BPC-157

BPC-157 is a synthetic 15-amino-acid peptide with a large and reasonably consistent animal literature behind it for tendon, muscle and gut repair — and no completed large randomised trial in humans. In Australia it is not registered on the ARTG, is handled as a prescription-only compounded preparation, and is prohibited in sport at all times.

What BPC-157 is

BPC-157 — "Body Protection Compound 157" — is a synthetic chain of fifteen amino acids, which is why the literature calls it a pentadecapeptide. Its sequence was derived from a larger protein fragment identified in human gastric juice, and that origin is part of why it attracted attention: researchers reported that the sequence remained stable in stomach acid, which is unusual for a peptide and raised the possibility of oral as well as injectable use.

Two things about that description are worth pinning down, because promotional material blurs them. First, BPC-157 does not occur in the body as a standalone molecule — it is a laboratory-made sequence based on a fragment of a naturally occurring protein, and "naturally derived" carries no implication of safety. Second, it is a research compound, not a therapy: it has never been approved as a medicine anywhere.

It is most often discussed for tendon, ligament and muscle injury, and for inflammatory conditions of the gut, and is usually supplied as a powder for reconstitution and injection. Online it is almost always paired with TB-500 — the two are covered together in our recovery-evidence explainer.

How it works

There is no single agreed mechanism. What exists is a set of overlapping pathways reported in rodent and cell studies. They are worth understanding, provided you hold on to the fact that a mechanism observed in a rat tendon is a hypothesis about humans, not a finding in humans.

The angiogenic pathway is the central claim. Healing tissue needs blood supply. Tendon and ligament are poorly vascularised, which is a large part of why they heal slowly and incompletely. BPC-157 has been reported to upregulate VEGFR2 — the principal receptor for vascular endothelial growth factor — and to activate the downstream signalling that drives endothelial cells to form new vessels. In animal models this shows up as more capillary formation at an injury site and faster restoration of blood flow around it. This is the most consistently reported effect and the one most of the rationale rests on.

Growth-factor and cell-migration pathways. Alongside the vascular effect, studies describe activation of the FAK–paxillin pathway, which governs how cells attach to their surroundings and crawl through them. That matters because repair depends on fibroblasts — the cells that lay down collagen — physically migrating into a damaged area and organising there. Related work reports increased expression of growth-hormone receptors on tendon fibroblasts, which would in principle make those cells more responsive to circulating growth factors. Again: reported in cells and rodents.

The nitric oxide system. A recurring theme in the literature is interaction with nitric oxide signalling, which regulates vessel dilation, blood flow and platelet behaviour. Some of the protective effects described in animal models — against blood-pressure disturbance, against certain drug-induced injuries — are attributed to this.

Gut-specific effects. The original interest was gastrointestinal. In rodent models of ulceration and colitis, BPC-157 has been reported to protect and repair the gut lining.

The picture is coherent: build vessels, move repair cells in, modulate inflammation. That coherence is why the compound is persuasive to read about, and why the next section matters more than this one.

What the human evidence actually shows

This is the part most content about BPC-157 skips or softens, and it is the single most important section on this page.

There are no completed large randomised controlled trials of BPC-157 in humans. Not for tendon injury, not for muscle tears, not for ligament damage, not for gut healing, not for anything else. That is not a matter of interpretation. The compound has never been through the process that would establish whether it works in people.

The evidence base is preclinical. A 2025 systematic review of BPC-157 in musculoskeletal injury identified roughly 35 preclinical studies against a single clinical study. In rats, results across tendon, muscle, ligament, nerve and gut models have been reasonably consistent and positive. The animal literature is genuine and it is not trivial in volume.

Early human work exists but is small and early-phase. BPC-157 was investigated in early-phase trials for inflammatory bowel disease. Early-phase trials are designed to look at tolerability and pharmacology in small numbers of people, not to demonstrate that a treatment works. No large efficacy programme followed.

Much of the preclinical work comes from a narrow base. A substantial share of the published animal literature originates from a small number of affiliated research groups — not an accusation of anything, but a standard reason scientists treat a body of work as needing independent replication.

There is no established effective human dose and no long-term human safety data, because the studies that would generate them have not been done.

The honest summary: a reasonably consistent rodent literature, a plausible mechanism, and no demonstration that any of it produces a meaningful result in a human being. Compounds that look this good in animals fail in human trials routinely — that is the normal outcome, not the exception. "Promising in rats" is where BPC-157 sits, and describing it as more than that goes beyond what anyone knows.

Regulatory status in Australia

BPC-157 is not on the Australian Register of Therapeutic Goods. It is not a TGA-registered medicine, which means the TGA has not evaluated it for quality, safety or efficacy. There is no approved Product Information document — no approved indications, no approved contraindications, no approved interaction list.

In practice it is handled as a prescription-only (Schedule 4) substance, supplied where at all as a compounded preparation made for an individual patient against a prescription from a registered practitioner. Compounding is lawful and long-established, but it is a different pathway from registration:

• The specific preparation has not been assessed by the TGA.
• Identity, sterility, potency and batch-to-batch consistency depend entirely on the compounding pharmacy's own quality systems.
• There is no post-market adverse event monitoring of the kind registered medicines carry.

Everything sold as BPC-157 outside that pathway — overseas websites, "research chemical" suppliers, gym-floor sources — is unlawful to supply for human use and unsafe to take, with no assurance of what is in the vial or whether it is sterile. The TGA has publicly raised concerns about unapproved peptides marketed online. See our explainers on peptide legality in Australia and compounded versus TGA-registered medicines.

Advertising prescription-only medicines to the public is restricted in Australia. A practitioner can discuss options with you in consultation; what you should not see is a compound like this promoted to consumers with claimed benefits.

Anti-doping status

BPC-157 is prohibited at all times in sport under the WADA Prohibited List, in category S0 (non-approved substances) — the category covering pharmacological substances with no current approval for human therapeutic use. Sport Integrity Australia's position is that it is banned and that a Therapeutic Use Exemption would not be granted, precisely because there is no approved therapeutic use to exempt.

That applies to athletes at every level who fall under an anti-doping code, not only to elite competitors. If you are tested, this is a sanctionable finding.

Who it is being studied for — and who it is not for

The research interest is in defined injury and disease models: tendon and ligament repair, muscle injury, nerve injury, and inflammatory bowel conditions. The popular use — accelerating recovery from a training injury in an otherwise healthy adult — sits outside anything that has been demonstrated.

Circumstances where a careful practitioner would be especially cautious, or would decline outright, include pregnancy and breastfeeding, a current or past cancer diagnosis, any undiagnosed lump or lesion, and any injury that has not been properly examined and imaged.

The cancer caution carries real weight. A compound whose central proposed action is promoting new blood-vessel growth is theoretically the wrong direction for anyone with abnormal tissue growth, since tumours also require a blood supply to expand. No human data establish that BPC-157 does this; none establish that it doesn't. Unresolved is the accurate word, and unresolved is a reason for caution rather than reassurance.

There is also a more mundane point. Most injuries people reach for peptides to fix have boring, evidence-backed treatments — accurate diagnosis first, then loading programmes, physiotherapy, sometimes surgery. If a clinic proposes an unregistered peptide before anyone has established what is actually torn, inflamed or degenerated, that is a meaningful warning sign.

Risks and considerations

Because human data are minimal, the risks are best described as unknown rather than proven low. Absence of reported harm in a literature this thin is not evidence of safety. The practical concerns:

• Product quality. Grey-market peptides have repeatedly been found mislabelled, degraded or contaminated. You cannot tell by looking.
• Injection risk. Reconstitution and injection introduce infection risk, injection-site reactions and the hazards of unsafe sharps handling.
• Unknown interactions. With no Product Information, no one can tell you how it behaves alongside your medicines or conditions.
• The angiogenesis question described above, which remains theoretical and unresolved.

For athletes, use is an anti-doping rule violation however the product was obtained. Anything unexpected goes to your treating practitioner promptly, not to a forum.

What to ask a doctor

• What exactly is my diagnosis, and how was it established — examination, imaging, or assumption?
• What are the proven treatments for this injury, and have I actually exhausted them?
• Given BPC-157 has no completed human efficacy trials, what are you basing the recommendation on?
• Is this compounded or registered? Which pharmacy makes it, and what quality accreditation do they hold?
• What are the realistic risks for someone with my history, and what would make you stop?
• What would tell us it is working, and by when? What is the stopping rule if it is not?
• If I compete in any tested sport, what does this do to my anti-doping status?
• How does this interact with my current medicines and conditions?
• What does the full course cost, including consultations, imaging and follow-up?

FAQ

Is BPC-157 approved as a medicine in Australia? No. It is not on the ARTG and has not been assessed by the TGA for human use. It is handled as a prescription-only (Schedule 4) substance and, where supplied, is compounded for an individual patient against a prescription.

Does it actually work in humans? Unproven. There are no completed large randomised controlled trials in people. The supporting evidence is overwhelmingly from rats and cell cultures. The honest position is that we do not know.

Is the animal evidence not good enough? Animal evidence tells you whether a compound is worth testing in humans — not whether it works in them. Most compounds that look effective in rodents fail when properly trialled in people. BPC-157 has not cleared that bar, because the trials have not been run.

Can athletes use it? No. It is prohibited at all times under WADA category S0, and Sport Integrity Australia indicates a Therapeutic Use Exemption would not be granted.

Is it the same as TB-500? No. They are different molecules with different proposed mechanisms — TB-500 relates to thymosin beta-4 and actin binding, BPC-157 to angiogenic and growth-factor signalling. They are discussed together because both are marketed for recovery and both share the same evidence problem. Combining unproven compounds multiplies the unknowns rather than the benefits.

What about the oral versions? Whether an oral preparation reaches tissue in a meaningful amount in humans has not been demonstrated. Oral does not mean safer or better characterised — it means the same unproven compound in a different format.

Should I look for a clinic that offers it? Start with the injury, not the compound. Get an accurate diagnosis from someone qualified to make one, then work through the treatments that have actually been shown to help. You can check a prescriber's AHPRA registration before any consultation, and compare doctor-supervised injury and recovery clinics once you know what you are looking for.